Whew. I can’t recall a year with as much drug channel tumult as we experienced in 2018. Hot topics included the ever-inflating gross-to-net bubble, the prospect for a world without rebates, the boom in copay accumulators, the specialty pharmacy industry’s slowdown, the completion of vertical integration mega deals, an aggressive federal government attempt to reform the entire industry, the still-looming challenge from Amazon, and much more. I’m exhausted just thinking about it all! I’m happy to say that Drug Channels was there to help you figure it out. Our site had another record year of readership. Drug Channels now has … Continue reading Drug Channels Outlook: What to Watch in 2019
On October 9, 2018, Drug Channels Institute will release The 2018–19 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. It’s the ninth edition of our annual evaluation of the economic and business realities driving U.S. drug distribution. This definitive, nonpartisan resource remains the most comprehensive tool for analyzing the industry. The 2018-19 edition has been thoroughly updated and revised with the latest information. This year, we are providing you with the opportunity to preorder the 2018-19 edition at special discounted prices. This means that you can be among the first to access our new report. Those who preorder will receive … Continue reading Preorder Now: Our 2018–19 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors
I can’t recall any period in my life when our country has been so divided and polarized. So just in time for our nation’s birthday, I’m happy to report some good news. When it comes to healthcare analysis, both Republicans and Democrats can agree on one thing: Drug Channels is the go-to source! Each political party’s major drug pricing policy document draws prominently from our research and writing. See below for the patriotic details of this historic bipartisan validation. Through the Drug Channels Institute, I strive to provide you with fact-based and balanced coverage. I’m proud that your friendly neighborhood … Continue reading Democrats and Republicans Agree: Drug Channels Is Awesome!
In three weeks, Drug Channels Institute will hit Las Vegas for Asembia’s 2018 Specialty Pharmacy Summit. Here are three ways that you can interact with us in Las Vegas: 1) Learn how Drug Channels can help your business. Drug Channels reaches a large, diverse audience throughout the pharmaceutical and healthcare industries. We have an engaged and growing audience of more than 21,000 readers who regularly open, click, forward, and share our content. Drug Channels has an engagement rate that is more than twice that of the average media platform. To discover how you can reach our audience, you can speak … Continue reading Connect With Drug Channels at #Asembia18
Hooray! We all made it through another 12 months. This year was stuffed with mega deals, political turmoil, the drug pricing blame game, generic market disruption, an ever-inflating gross-to-net bubble, and Amazon mania. Through it all, Drug Channels was there to help you figure it out. I’m pleased to report that we had another record year. Drug Channels now has more than 20,000 subscribers, including nearly 5,000 @DrugChannels Twitter followers. (Follow me there for daily updates.) Thank you, dear readers, for welcoming me into your inboxes and browsers each week. I’ve had a blast writing Drug Channels and also hope … Continue reading Drug Channels Outlook: What to Watch in 2018